Margaret Malone1, Sharon A Alger-Mayer. 1. Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208-3492, USA. malonem@acp.edu
Abstract
BACKGROUND: Bariatric surgery, commonly gastric bypass, is an effective intervention in achieving sustained weight loss in patients with a body mass index (BMI) >40 kg/m(2). Currently, there are few data in the literature describing medication use after bariatric surgery. OBJECTIVE: To document the change in medication use patterns over a 2-year period in patients who had gastric bypass surgery. METHODS: Institutional review board approval was obtained for this ongoing, prospective longitudinal study. Adults (>18 y) scheduled for gastric bypass surgery were recruited. Clinical and demographic data, including age, gender, weight, height, BMI, number of obesity-related comorbidities, and number of medications and nutritional supplements, were obtained by medical chart review. RESULTS: One hundred fourteen patients (87 females) were recruited. The mean +/- SD age was 45 +/- 9 years. Patients had multiple obesity-related comorbid diseases for which they were receiving medication. Drug therapy for diabetes and hypertension was significantly reduced (p < 0.05). All patients were required to take additional nutritional supplements and medications associated with surgery postoperatively. CONCLUSIONS: Bariatric surgery has a positive benefit in terms of reduction intake of medication associated with obesity-related comorbid disease. However, there is limited reduction in the overall number of drugs and supplements being consumed by the patient, especially during the first year postoperatively.
BACKGROUND: Bariatric surgery, commonly gastric bypass, is an effective intervention in achieving sustained weight loss in patients with a body mass index (BMI) >40 kg/m(2). Currently, there are few data in the literature describing medication use after bariatric surgery. OBJECTIVE: To document the change in medication use patterns over a 2-year period in patients who had gastric bypass surgery. METHODS: Institutional review board approval was obtained for this ongoing, prospective longitudinal study. Adults (>18 y) scheduled for gastric bypass surgery were recruited. Clinical and demographic data, including age, gender, weight, height, BMI, number of obesity-related comorbidities, and number of medications and nutritional supplements, were obtained by medical chart review. RESULTS: One hundred fourteen patients (87 females) were recruited. The mean +/- SD age was 45 +/- 9 years. Patients had multiple obesity-related comorbid diseases for which they were receiving medication. Drug therapy for diabetes and hypertension was significantly reduced (p < 0.05). All patients were required to take additional nutritional supplements and medications associated with surgery postoperatively. CONCLUSIONS: Bariatric surgery has a positive benefit in terms of reduction intake of medication associated with obesity-related comorbid disease. However, there is limited reduction in the overall number of drugs and supplements being consumed by the patient, especially during the first year postoperatively.
Authors: Jan Peter Yska; Susanne van der Linde; Véronique V Tapper; Jan A Apers; Marloes Emous; Erik R Totté; Bob Wilffert; Eric N van Roon Journal: Obes Surg Date: 2013-06 Impact factor: 4.129
Authors: Jan Peter Yska; Jacquelien T M Wanders; Blessing Odigie; Jan A Apers; Marloes Emous; Erik R E Totté; E Christiaan Boerma; Froukje L Ubels; Herman J Woerdenbag; Henderik W Frijlink; Bob Wilffert; Eric N van Roon Journal: Eur J Hosp Pharm Date: 2019-02-15
Authors: Amy L Kennedy; Tracy Nelson; Stefan Pettine; Benjamin F Miller; Karyn L Hamilton; Elise L Donovan Journal: Obes Surg Date: 2014-05 Impact factor: 4.129
Authors: Yufei Chen; Carrie C Lubitz; Scott A Shikora; Richard A Hodin; Randall D Gaz; Francis D Moore; Travis J McKenzie Journal: Obes Surg Date: 2015-04 Impact factor: 4.129
Authors: Jan Peter Yska; Douwe H van der Meer; Albert R Dreijer; Willeke Eilander; Jan A Apers; Marloes Emous; Erik R E Totté; Bob Wilffert; Eric N van Roon Journal: Eur J Clin Pharmacol Date: 2015-11-03 Impact factor: 2.953